نتائج البحث 401-410 من 7621 لعملية البحث عن Residual
placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...
The purpose of this study is to extend the follow up on the BEAUTY study (MC1137) cohort and collect additional blood samples to evaluate for minimal residual ...
... residual colon/rectum/pouch as the primary disease site. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib to To Treat ...
This drug combination is still experimental and is not approved by the FDA. Discontinuation of pirtobrutinib and venetoclax based on minimal residual disease ( ...
Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring ...
The purpose of this study is to evaluate a low-cost Contrast Enhanced Digital Mammogram (CEDM) protocol as a supplemental screening method to standard ...
This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns ...
... residual colon/rectum/pouch as the primary disease site. A Study to Evaluate the Feasibility of Intraoperative Microdialysis (tissue sampling) during ...
Some patients undergoing trigger finger surgery with a pre-existing Dupuytren's cord may develop a thickened surgical scar after surgery, which can cause ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.